HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING.
Luo X, Donnelly CR, Gong W, Heath BR, Hao Y, Donnelly LA, Moghbeli T, Tan YS, Lin X, Bellile E, Kansy BA, Carey TE, Brenner JC, Cheng L, Polverini PJ, Morgan MA, Wen H, Prince ME, Ferris RL, Xie Y, Young S, Wolf GT, Chen Q, Lei YL. HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J Clin Invest. 2020 04 01; 130(4):1635-1652.